These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 1438794)

  • 1. Experimental therapeutic studies with miltefosine in rats and mice.
    Hilgard P; Stekar J; Voegeli R; Harleman JH
    Prog Exp Tumor Res; 1992; 34():116-30. PubMed ID: 1438794
    [No Abstract]   [Full Text] [Related]  

  • 2. Tumor heterogeneity and chemosensitivity to cyclophosphamide, vinblastine and hexadecylphosphocholine.
    Angres G; Scherf HR; Schmähl D
    Cancer Treat Rev; 1990 Sep; 17(2-3):339-45. PubMed ID: 2272049
    [No Abstract]   [Full Text] [Related]  

  • 3. Interstitial chemotherapy of experimental gliomas.
    Zeller WJ; Bauer S; Remmele T; Wowra B; Sturm V; Stricker H
    Cancer Treat Rev; 1990 Sep; 17(2-3):183-9. PubMed ID: 2272032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New pharmaceuticals: miltefosine.
    Hilgard P
    Anticancer Drugs; 1990 Dec; 1(2):185. PubMed ID: 2131052
    [No Abstract]   [Full Text] [Related]  

  • 5. Alkylphosphocholines: a new class of membrane-active anticancer agents.
    Hilgard P; Klenner T; Stekar J; Unger C
    Cancer Chemother Pharmacol; 1993; 32(2):90-5. PubMed ID: 8485813
    [No Abstract]   [Full Text] [Related]  

  • 6. Miltefosine: a novel treatment option for mast cell-mediated diseases.
    Maurer M; Magerl M; Metz M; Weller K; Siebenhaar F
    J Dermatolog Treat; 2013 Aug; 24(4):244-9. PubMed ID: 22385017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Miltefosine in recurrent cutaneous breast cancer.
    Clive S; Leonard RC
    Lancet; 1997 Mar; 349(9052):621-2. PubMed ID: 9057742
    [No Abstract]   [Full Text] [Related]  

  • 8. D-21266, a new heterocyclic alkylphospholipid with antitumour activity.
    Hilgard P; Klenner T; Stekar J; Nössner G; Kutscher B; Engel J
    Eur J Cancer; 1997 Mar; 33(3):442-6. PubMed ID: 9155530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of oral miltefosine in patients with squamous cell head and neck cancer.
    Verweij J; Gandia D; Planting AS; Stoter G; Armand JP
    Eur J Cancer; 1993; 29A(5):778-9. PubMed ID: 8471342
    [No Abstract]   [Full Text] [Related]  

  • 10. Miltefosine suppresses inflammation in a mouse model of inflammatory bowel disease.
    Verhaar AP; Wildenberg ME; te Velde AA; Meijer SL; Vos AC; Duijvestein M; Peppelenbosch MP; Hommes DW; van den Brink GR
    Inflamm Bowel Dis; 2013 Aug; 19(9):1974-82. PubMed ID: 23811637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loco-regional control of cutaneous metastases of malignant melanoma by treatment with miltefosine (Miltex).
    Ragnarsson-Olding B; Djureen-Mårtensson E; Månsson-Brahme E; Hansson J
    Acta Oncol; 2005; 44(7):773-7. PubMed ID: 16227173
    [No Abstract]   [Full Text] [Related]  

  • 12. [Treatment of visceral leishmaniasis: efficacy and limits of miltefosine].
    Gangneux JP; Marty P
    Sante; 2001; 11(4):257-8. PubMed ID: 11861203
    [No Abstract]   [Full Text] [Related]  

  • 13. [[Treatment with Miltex for metastatic skin lesions in breast cancer] ].
    Moĭseenko VM; Orlova RV; Ermakova NA; Protsenko SA
    Vopr Onkol; 2000; 46(5):600-3. PubMed ID: 11202195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo antitumoral activity of alkylphosphonates.
    Ries UJ; Fleer EA; Breiser A; Unger C; Stekar J; Fenneberg K; Eibl H
    Eur J Cancer; 1992; 29A(1):96-101. PubMed ID: 1445752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hexadecylphosphocholine, a new ether lipid analogue. Studies on the antineoplastic activity in vitro and in vivo.
    Unger C; Damenz W; Fleer EA; Kim DJ; Breiser A; Hilgard P; Engel J; Nagel G; Eibl H
    Acta Oncol; 1989; 28(2):213-7. PubMed ID: 2736110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II trial of miltefosine in patients with cutaneous T-cell lymphoma.
    Dumontet C; Thomas L; Bérard F; Gimonet JF; Coiffier B
    Bull Cancer; 2006 Nov; 93(11):E115-8. PubMed ID: 17145574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer.
    Leonard R; Hardy J; van Tienhoven G; Houston S; Simmonds P; David M; Mansi J
    J Clin Oncol; 2001 Nov; 19(21):4150-9. PubMed ID: 11689583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Miltefosine--discovery of the antileishmanial activity of phospholipid derivatives.
    Croft SL; Engel J
    Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S4-8. PubMed ID: 16904717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hexadecylphosphocholine: a new and selective antitumor drug.
    Eibl H; Unger C
    Cancer Treat Rev; 1990 Sep; 17(2-3):233-42. PubMed ID: 2272038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic behavior and antineoplastic activity of liposomal hexadecylphosphocholine.
    Kaufmann-Kolle P; Drevs J; Berger MR; Kötting J; Marschner N; Unger C; Eibl H
    Cancer Chemother Pharmacol; 1994; 34(5):393-8. PubMed ID: 8070005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.